Hyun-Bae Jie

CEO & CTO at Levatio Therapeutics

Speaker

Hyun-Bae Jie studied molecular biology and cellular immunology and is an expert in cancer immunotherapy, autoimmune diseases, and asthma (more than 30 years). He received his Ph.D. from The Chicago Medical School and did postdoctoral work at The Scripps Research Institute, Harvard Medical School, Cincinnati Children’s Hospital Medical Center, and University of Pittsburgh Cancer Institute (UPCI). During his time at UPCI's Robert Ferris laboratory, he found that treatment with cetuximab upregulates various immune checkpoint receptors at the tumor site in patients with head and neck cancer. Based on his studies, three clinical trials (Ipilimumab, Nivolumab monotherapy, and Nivolumab+Cetuximab combination therapy) were initiated for treating patients with head and neck cancer. From 2014 to 2021, he worked on immuno-oncology drug development at OncoMed Pharmaceutical and Ambrx. In 2021, he founded Levatio Therapeutics to develop circular RNA platform technology and therapeutics to treat patients with cancer and autoimmune diseases.